trending Market Intelligence /marketintelligence/en/news-insights/trending/Sf8wOvJ6pAv_an25h4ux_g2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Amunix licenses technology to Roche for $40M to develop non-cancer treatments

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Amunix licenses technology to Roche for $40M to develop non-cancer treatments

Amunix Operating Inc., a private biopharmaceutical company, entered an agreement to license its Xten technology platform to Roche Holding AG.

Roche intends to use the Xten technology platform, which directs infection-fighting cells in the immune system, to develop non-cancer treatments.

Switzerland-based Roche will pay the Mountain View, Calif.-based Amunix $40 million upfront and up to $1.5 billion in development and sales-based milestones, plus royalties on sales of commercialized products.

"This agreement further validates our foundational Xten technology and its continued potential for biopharmaceutical partners seeking to develop drugs with augmented half-life and low associated immunogenicity," said Amunix CEO Angie You.